Synairgen PLC

Synairgen making headway


  • Focused on respiratory disease
  • Two drug candidates, one developed in-house, one by a partner
  • Financially well set to progress its key asset, analyst says
lung x-ray

Quick facts: Synairgen PLC

Price: 8.25 GBX

Market: AIM
Market Cap: £9.03 m

Respiratory specialist

Synairgen plc (LON:SNG) is currently running a two-part phase II trial evaluating SNG001. This is an inhaled interferon beta drug candidate designed for people with chronic obstructive pulmonary disease (COPD) who are also suffering cold or flu infections.

It has completed the first part of its SG015 study, assessing the safety of the treatment. The second instalment is underway at 15 separate sites. Synairgen expects the trial to continue into the 2019/20 peak period for cold and flu.

In the latest release (July 24) the company said it was making encouraging early progress with the phase II clinical trial.  

Chief executive Richard Marsden said the company is “successfully capturing marked changes” in patients with COPD that also have the aforementioned viruses.

“We have previously shown that inhaled IFN-beta boosts the lungs' antiviral defences in COPD patients and the magnitude of the symptom changes being observed so far in the current trial puts us in a good position to determine the potential benefit of inhaled IFN-beta in this patient population," the Synairgen CEO added.



The company’s Australian partner has completed phase I trials and toxicology on a LOXL2 inhibitor developed by Synairgen.

This now paves the way for Pharmaxis to advance discussions with potential partners for the drug, which has been developed to treat non-alcoholic liver disease (NASH) and a rare lung condition.

The company retains a 17% “carried interest” in the asset.


Synairgen’s BioBank

Over the years, Synairgen has accumulated an extensive bank comprised of blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma or COPD. Using this resource, the company has developed a number of advanced tissue models.

It uses these models to:

•        Discover novel drug targets

•        Identify disease-related lesions and underlying molecular mechanisms

•        Conduct proof of concept testing and validation of novel drug targets

•        Conduct screening assays for novel drug targets and lead target selection

•        Provide support for clinical trial activities


Financially solid

The company ended last year with £5.33mln in the bank, having raised £2.7mln.


What the broker says

Mark Brewer of small-cap specialist finnCap said in Feburary that year-end cash of £5.3mln was “sufficient to more than cover the cost of the ongoing phase IIa study of SNG001”. On the slower than expected sign-up rate for the trial, he added: “We are hugely reassured by the fact that all patients enrolled are virus-positive, which increases the probability of SNG001 showing a drug-related effect.”

Brewer’s price target for the stock is 54p. The shares are currently changing hands for 15p.


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...



Synairgen's phase II trial on lead COPD drug 'progressing well'

Synairgen PLC's (LON:SNG) Richard Marsden tells Proactive London's Andrew Scott  the respiratory drug discovery and development company, is well-poised to complete the phase II trial on its lead candidate. The trial is expected to complete dosing in Q1 next year with results available in...

3 weeks, 1 day ago

3 min read